|Bid||87.39 x 900|
|Ask||87.42 x 800|
|Day's range||83.13 - 87.44|
|52-week range||81.54 - 208.99|
|Beta (5Y monthly)||1.38|
|PE ratio (TTM)||N/A|
|Earnings date||16 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||186.75|
In the healthcare markets, much time and energy have been focused on COVID-19. But there are some amazing opportunities outside the COVID space.
Here we look at three stocks, PKI, TMO and TXG, with robust genome sequencing capabilities that investors can keep a watch on.
Despite crushing the S&P 500 -- 180% to 63% -- since its September 2019 IPO, 10x Genomics' (NASDAQ: TXG) shares have only experienced 6% growth year to date. The company has rapidly become a cornerstone of biomedical research with its laboratory devices capable of profiling individual cells, but investors recently seem to have shrugged. Does the stock price just need a few quarters to catch up to its valuation?